[1] Nguyen NB, Nguyen Thi HH, Thi HL, et al.Results of acute cerebral infarction treatment with hyperbaric oxygen therapy, 2020-2022[J]. Int Marit Health. 2023,74(4):265-271. [2] 董屹,鲍勇,胡承志,等.重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死预后影响因素及血清胱抑素C水平对预后预测价值[J].临床军医杂志, 2023, 51(4):404-407. [3] 江雪,江海燕.吡拉西坦联合舒血宁注射液对高血压并脑梗死患者血液流变学及血清Hcy和hs-CRP水平的影响[J].河北医学, 2022, 28(2):331-336. [4] 张占军,李占龙,郭慧欣.疏血通注射液联合吡拉西坦对高血压合并急性脑梗死患者的临床疗效及安全性观察[J].贵州医药, 2022, 46(10):1532-1534. [5] 张丽娜,谭逸海,丁薇,等.疏血通注射液联合阿替普酶静脉溶栓治疗急性脑梗死疗效与安全性的Meta分析[J].中西医结合心脑血管病杂志, 2024, 22(4):607-613. [6] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性卒中诊治指南2023[J].中华神经科杂志, 2024, 57(6):523-559. [7] Öncül M, Elkıran Ö, Karakurt C, et al.Effect of Piracetam and Iron Treatment on Heart Rate Variability in Patients With Breath-Holding Spell[J]. Pediatr Neurol. 2024 ,156:53-58. [8] 李万华,王绍谦,刘艳,等.苦碟子注射液联合吡拉西坦治疗急性脑梗死的临床研究[J].现代药物与临床, 2023, 38(5):1113-1117. [9] Mani V, Rabbani SI, Shariq A, et al.Piracetam as a Therapeutic Agent for Doxorubicin-Induced Cognitive Deficits by Enhancing Cholinergic Functions and Reducing Neuronal Inflammation, Apoptosis, and Oxidative Stress in Rats[J]. Pharmaceuticals (Basel). 2022 ,15(12):1563. [10] Zhao JY, Wang XL, Wang XF, et al.[Meta-analysis and GRADE evaluation of Shuxuetong Injection in treatment of stroke in progressive][J]. Zhongguo Zhong Yao Za Zhi. 2022 ,47(3):807-818. [11] 李强,李博,王宏,等.疏血通注射液治疗急性缺血性脑卒中的有效性和安全性系统评价[J].中国循证心血管医学杂志, 2023, 15(12):1287-1294. [12] Chen L, Liu F, Tian X, et al.Impact of cerebral microbleeds on cognitive functions and its risk factors in acute cerebral infarction patients[J]. Neurol Res. 2023,45(6):564-571. [13] 赖宗强,赖吴芳,韦文兴,等. 重组水蛭素抗ApoE-/-小鼠动脉粥样硬化的研究[J]. 河北医药,2024,46(11):1617-1621. [14] 尚曙玉,刘垚蕾,刘景沣,等. 地龙对糖尿病肾病大鼠肝脏和肾脏保护作用的研究[J]. 黄河科技学院学报,2024,26(2):26-32. [15] 吴婉玉,左毅,廖峻. 疏血通注射液联合吡拉西坦对高血压并急性脑梗死患者的临床疗效[J]. 中成药,2021,43(5):1195-1199. |